<DOC>
	<DOCNO>NCT00768859</DOCNO>
	<brief_summary>To determine activity combination paclitaxel , trastuzumab carboplatin neo-adjuvant treatment patient stage II III HER2 positive breast cancer</brief_summary>
	<brief_title>Trastuzumab Neo-adjuvant Regimen HER2+ Breast Cancer - TRAIN Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm infiltrate breast cancer . Stage II stage III breast cancer.28 'Locally advance breast cancer ' patient consequently eligible , include ipsilateral supraclavicular lymph node metastasis . N1 status must demonstrate either fine needle aspiration axillary lymph node metastasis &gt; 2 mm diameter sentinel node biopsy . Stage IIA patient eligible tumor &gt; 3 cm diameter tumor 2 3 cm diameter breast conserve surgery possible . Overexpression and/or amplification HER2 invasive component core biopsy , accord one follow definition : &gt; 10 % invasive tumor cell show strong complete circumferential membrane staining ( score 3+ ) &gt; 10 % invasive tumor cell show moderate complete circumferential membrane staining ( score 2+ ) demonstrate HER2 gene amplification define FISH ratio HER2 gene copy chromosome 17 signal &gt; 2.2 . &gt; 5 HER2 gene copy per nucleus CISH analysis . Patients negative equivocal overall result ( FISH test ratio &lt; 2.2 , &lt; 6.0 HER2 gene copy per nucleus ) staining score 0,1+ , 2+ 3+ ( 30 % le neoplastic cell ) IHC eligible participation trial . Age ≥18 Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 ( Appendix B ) Adequate bone marrow function ( ANC &gt; 1.0 x 109/l , platelet &gt; 100 x 109/l ) Adequate hepatic function ( ALAT , ASAT bilirubin &lt; 2 time upper limit normal ) Adequate renal function ( creatinine clearance &gt; 60 ml/min ) LVEF ≥50 % measure echocardiography MUGA Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Signed write informed consent No previous radiation therapy chemotherapy No malignancy except carcinoma situ , unless malignancy treat ≥5 year ago curative intent without use chemotherapy radiation therapy . No current pregnancy breastfeeding . Women childbearing potential must use adequate contraceptive protection . No evidence distant metastasis . Staging examination must include chest radiograph , ultrasound examination liver isotope bone scan . Abnormal uptake isotope bone scan accept MRI , CTscan , plain radiograph exclude bone metastasis . No concurrent anticancer treatment another investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>neo-adjuvant</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>